Update on targeted therapy - Focus on monoclonal antibodies

Journal of Pharmacy Practice

Volumn 21, Issue 1, 2008, Pages 4-16

  Toma, Meredith B ^a   Medina, Patrick J ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); Cellular dependent cytotoxicity (CDC); Epidermal growth factor receptor (EGFR); Human epidermal growth factor receptor (HER); Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COUGHING; CYTOPENIA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; HEAD AND NECK CANCER; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; INJECTION SITE REACTION; INSOMNIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROTEINURIA; PRURITUS; RASH; REVIEW; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 41549109369     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008315058     Document Type: Review

References (39)

1. Scheinberg DA, Mulford DA, Jurcic JG, Sgouros G., Junghans RP Antibody therapies of cancer. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 66-698.
2. American Medical Association. Monoclonal antibodies. http://www.ama-assn. org/ama/pub/category/13280.html. Updated August 7, 2007. Accessed November 28, 2007.
3. Rotea W. Jr, Saad ED Targeted drugs in oncology: new names, new mechanisms, new paradigm. Am J Health Syst Pharm. 2003 ; 60: 1233-1245.
4. Giles F., Estey E., O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003 ; 98: 2095-2104.
5. Villamor N., Montserrat E., Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003 ; 30: 424-433.
6. Sharkey RM, Goldenberg DM, Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006 ; 56: 226-243.
7. Cheson BD, Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003 ; 101: 391-398.
8. Cersosimo RJ Monoclonal antibodies in the treatment of cancer, Part 2. Am J Health Syst Pharm. 2003 ; 60: 1631-1643.
9. Mylotarg (gemtuzumab) [product information]. Philadelphia, PA: Wyeth Pharmaceuticals ; 2006.
10. Plosker GL, Figgitt DP Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003 ; 63: 803-843.
11. Cersosimo RJ Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm. 2003 ; 60: 1531-1548.
12. Rituxan (rituximab) [product information]. South San Francisco, CA: Genentech ; 2007.
13. Middleton HJ, Mollee P., Bird R., Mills A., Marlton P., Gill D. Accelerated Delivery of Rituximab Is Safe on an OutPatient Basis [abstract]. Blood. 2005 ; 106: 4777.
14. Provencio M., Cerdeira S., Bonilla F., Sánchez A., España P. Rapid-infusion rituximab in lymphoma treatment. Ann Oncol. 2006 ; 17: 1027-1028.
15. Salar A., Casao D., Cervera M., et al. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol. 2006 ; 77: 338-340.
16. Sehn LH, Donaldson J., Filewich A., et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 2007 ; 109: 4171-4173.
17. Hernandez MC, Knox SJ Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol. 2003 ; 30 (suppl 17). 6-10.
18. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001 ; 19: 3918-3928.
19. Frampton JE, Wagstaff AJ Alemtuzumab [Discussion]. Drugs. 2003 ; 63: 1229-1246.
20. Hongtao Z., Berezov A., Qiang W., et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007 ; 117: 2051-2058.
21. Gross ME, Shazer RL, Agus DB Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 ; 31 (suppl 3). 9-20.
22. Syed S., Rowinsky E. The new generation of targeted therapies for breast cancer [Discussion]. Oncology (Huntington). 2003 ; 17: 1339-1352.
23. Rowinsky EK Signal events: cell signal transduction and its inhibition in cancer. Oncologist. 2003 ; 8 (suppl 3). 5-17.
24. Finley RS Overview of targeted therapies for cancer. Am J Health Syst Pharm. 2003 ; 60 (suppl 9). S4 - S10.
25. Reynolds NA, Wagstaff AJ Cetuximab: in the treatment of metastatic colorectal cancer [Discussion]. Drugs. 2004 ; 64: 109-121.
26. Reichert JM, Valge-Archer VE Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007 ; 6: 349-355.
27. Iannello A., Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anticancer monoclonal antibodies. Cancer Metastasis Rev. 2005 :; 24: 487-499.
28. Bonner JA, Harari PM, Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 ; 354: 567-578.
29. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 ; 351: 337-345.
30. Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005 ; 23: 5235-5246.
31. Carteni G., Fiorentino R., Vecchione L., Chiurazzi B., Battista C. Panitumumab a novel drug in cancer treatment. Ann Oncol. 2007 ; 18 (suppl 6). vi16-21.
32. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 ; 25: 1658-1664.
33. Vectibix (panitumumab) [product information]. Thousand Oaks, CA: Amgen ; 2007.
34. Treish I., Schwartz R., Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000 ; 57: 2063-2079.
35. Leyland-Jones B., Gelmon K., Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003 ; 21: 3965-3971.
36. Zondor SD, Medina PJ Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004 ; 38: 1258-1264.
37. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 ; 350: 2335-2342.
38. Avastin (bevacizumab) [product information]. San Francisco, CA: Genentech ; 2006.
39. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007 ; 25: 2691-2695.